Jeff Yass Susquehanna International Group
Jeff Yass is a co-founder of Susquehanna International Group (SIG), a major global trading and market-making firm. SIG is known for options expertise, quantitative trading, and a training culture grounded in probabilistic decision-making. Yass’s firm is influential across derivatives markets even though it is less of a traditional long-only stock-picking franchise.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$2.58B |
| 2 |
iShares 20+ Year Treasury Bond ETF
TLT
|
+$1.43B |
| 3 |
Boeing
BA
|
+$283M |
| 4 |
CrowdStrike
CRWD
|
+$251M |
| 5 |
Coinbase
COIN
|
+$235M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Apple
AAPL
|
+$845M |
| 2 |
Invesco QQQ Trust
QQQ
|
+$837M |
| 3 |
Broadcom
AVGO
|
+$691M |
| 4 |
NVIDIA
NVDA
|
+$662M |
| 5 |
Vanguard FTSE Developed Markets ETF
VEA
|
+$660M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 93.75% |
| 2 | Technology | 1.85% |
| 3 | Consumer Discretionary | 1.02% |
| 4 | Financials | 0.76% |
| 5 | Communication Services | 0.62% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
11201
CALL
ProQR Therapeutics
PRQR
$326M
| $68.1K | ﹤0.01% |
37,400
+13,000
| +53% | +$24.4K |
|
11202
CALL
Talphera
TLPH
$62.8M
| $67.5K | ﹤0.01% |
78,500
+900
| +1% | +$825 |
|
11203
PharmaCyte Biotech
PMCB
$5.62M
| $67.3K | ﹤0.01% |
35,228
-19,606
| -36% | -$36.5K |
|
11204
The RealReal
REAL
$1.34B
| $67.1K | ﹤0.01% |
21,360
-41,742
| -66% | -$125K |
|
|
BLDP
11205
Ballard Power Systems
BLDP
$672M
| $67K | ﹤0.01% |
37,231
-46,115
| -55% | -$92.3K |
|
|
BLUE
11206
PUT
DELISTED
bluebird bio
BLUE
| $67K | ﹤0.01% |
6,440
-10,460
| -62% | -$174K |
|
11207
DB Gold Double Short ETN due Feb 15 2038
DZZ
$3.04M
| $66.9K | ﹤0.01% |
38,189
-3,740
| -9% | -$6.93K |
|
11208
TELA Bio
TELA
$30.3M
| $66.8K | ﹤0.01% |
26,401
-60,919
| -70% | -$217K |
|
11209
Angi Inc
ANGI
$203M
| $66.5K | ﹤0.01% |
2,579
-1,674
| -39% | -$40.3K |
|
11210
Cocrystal Pharma
COCP
$21.8M
| $66.5K | ﹤0.01% |
37,800
+12,748
| +51% | +$24.8K |
|
11211
Five Point Holdings
FPH
$369M
| $66.3K | ﹤0.01% |
+15,983
| New | +$50.8K |
|
11212
Compass Therapeutics
CMPX
$443M
| $66.3K | ﹤0.01% |
36,037
-14,418
| -29% | -$18K |
|
11213
NN Inc
NNBR
$283M
| $66.2K | ﹤0.01% |
16,973
-17,628
| -51% | -$63.5K |
|
|
VOXX
11214
PUT
DELISTED
VOXX International Corporation Class A
VOXX
| $66.1K | ﹤0.01% |
+10,400
| New | +$40.2K |
|
|
TE
11215
CALL
T1 Energy
TE
$1.42B
| $66.1K | ﹤0.01% |
68,100
+10,100
| +17% | +$13.8K |
|
11216
SES AI
SES
$193M
| $65.9K | ﹤0.01% |
103,060
-72,711
| -41% | -$75.9K |
|
|
VERV
11217
CALL
DELISTED
Verve Therapeutics
VERV
| $65.8K | ﹤0.01% |
+13,600
| New | +$79K |
|
11218
PMV Pharmaceuticals
PMVP
$65.2M
| $65.8K | ﹤0.01% |
44,160
-42,457
| -49% | -$65.6K |
|
11219
Solitario Resources
XPL
$76.2M
| $65.6K | ﹤0.01% |
93,753
+48,454
| +107% | +$39K |
|
11220
CALL
Cellectar Biosciences
CLRB
$24.1M
| $65.5K | ﹤0.01% |
+1,020
| New | +$67.3K |
|
11221
CALL
Vivani Medical
VANI
$128M
| $65.3K | ﹤0.01% |
55,800
+26,100
| +88% | +$32.6K |
|
11222
PUT
E.W. Scripps
SSP
$301M
| $65.3K | ﹤0.01% |
29,000
+18,000
| +164% | +$46.1K |
|
11223
CALL
Vanda Pharmaceuticals
VNDA
$317M
| $65.2K | ﹤0.01% |
+13,900
| New | +$74.5K |
|
|
IRD
11224
Opus Genetics
IRD
$304M
| $65.2K | ﹤0.01% |
49,755
+3,178
| +7% | +$4.89K |
|
11225
PUT
Organogenesis Holdings
ORGO
$221M
| $64.9K | ﹤0.01% |
22,700
-4,800
| -17% | -$13.5K |
|
Similar funds
Jeff Yass's Q3 2024 Portfolio in Review
As of Q3 2024, Jeff Yass held 13,475 positions worth $572B, up 6.6% from $537B the previous quarter. Its ten largest holdings account for 25% of the portfolio.
Jeff Yass's Q3 2024 filing shows 1,572 new, 5,247 increased, 4,924 reduced and 1,625 closed positions. Its largest new stake was Camtek: 408,771 shares worth $32.6M. The largest sale was Apple, an estimated $845M.
By sector, the portfolio is most concentrated in Miscellaneous at 94% of assets, up from 93% a quarter earlier, followed by Technology and Consumer Discretionary.
- Jeff Yass's largest Q3 2024 buy was Camtek: 408,771 shares worth $32.6M.
- Jeff Yass added most to State Street SPDR S&P 500 ETF Trust in Q3 2024, an estimated $2.58B increase.
- Jeff Yass's biggest Q3 2024 reduction was Apple, cutting an estimated $845M.
- Jeff Yass fully exited iShares Convertible Bond ETF in Q3 2024, selling an estimated $80.5M.
- Jeff Yass's ten largest holdings make up 25% of its $572B portfolio in Q3 2024.
- Jeff Yass opened 1,572 new positions and closed 1,625 in Q3 2024.
- Jeff Yass's portfolio value rose 6.6% quarter-over-quarter to $572B.
Based on Susquehanna International Group's 13F filing for Q3 2024, filed 14 Nov 2024.